BPZE1 Publications

Title
• BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a Bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study. World Vaccine Congress Europe, Barcelona, Spain, October 18, 2023
• Live attenuated Bordetella pertussis intranasal vaccine (BPZE1). World Vaccine Congress, April 6, 2023
• Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial
• Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
• Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
• Livening up pertussis vaccine development
• IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
• A Phase I Clinical Study of a Live Attenuated Bordetella Pertussis Vaccine - BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male Volunteers
• B-cell responses after intranasal vaccination with the novel attenuated Bordetella Pertussis vaccine strain BPZE1 in a randomized phase I clinical trial
• Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella Pertussis Disease and Infection
• Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice
• New pertussis vaccination approaches: en route to protect newborns?
• Pertussis: acellular, whole-cell, new vaccines, what to choose?
• Live attenuated vaccines against pertussis
• Dose response of attenuated Bordetella Pertussis BPZE1-induced protection in mice
• Live Attenuated B. pertussis as a Single-Dose Nasal Vaccine against Whooping Cough.
• Highly Attenuated Bordetella Pertussis Strain BPZE1 as a Potential Live Vehicle for Delivery of Heterologous Vaccine Candidates
• A Live Attenuated Bordetella Pertussis Candidate Vaccine Does Not Cause Disseminating Infection in Gamma Interferon Receptor Knockout Mice
• T- and B-Cell-Mediated Protection Induced by Novel, Live Attenuated Pertussis Vaccine in Mice. Cross Protection against Parapertussis
• Dual mechanism of protection by live attenuated Bordetella Pertussis BPZE1 against Bordetella bronchiseptica in mice
• Attenuated Bordetella Pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models
• Immunogenicity of Live Attenuated B. pertussis BPZE1 Producing the Universal Influenza Vaccine Candidate M2e
• Attenuated Bordetella Pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism
• A live, attenuated Bordetella Pertussis vaccine provides long-term protection against virulent challenge in a murine model
• Genetic stability of the live attenuated Bordetella Pertussis vaccine candidate BPZE1
• Attenuated Bordetella Pertussis Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced Migration and Drives a Th1/Th17 Response
• Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1
• Attenuated Bordetella Pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model
• Attenuated Bordetella Pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route
• Possible Options for New Pertussis Vaccines
• Live Attenuated B. pertussis BPZE1 Rescues the Immune Functions of Respiratory Syncytial Virus Infected Human Dendritic Cells by Promoting Th1/Th17 Responses